DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Glen Moller has joined the Company’s Board of Directors.
| CAESAREA, Israel, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Glen Moller has joined the Company’s Board of Directors. Mr. Moller is a highly regarded healthcare executive with a 25-year career leading healthcare and technology businesses, including a background in managed care and in technology enabled health services. He has held leadership positions in some of the largest healthcare companies in the U.S., including at Centene Corporation and Express Scripts Insurance Company. 
Mr. Moller is currently an Operating Partner at Frazier Healthcare Partners, a leading provider of growth and venture capital to healthcare companies with a total of $4 billion in capital under management. Previously, he served as the Chief Executive Officer and Board Member of ArroHealth, Inc., a premier provider of risk adjustment services, population health analytics, mass medical data aggregation, and human and computer-assisted medical chart analysis. Under Mr. Moller’s leadership, ArroHealth became one of the fastest growing HCIT companies in the country and succeeded in two successful investor exits. Prior to ArroHealth, Mr. Moller served as Chief Executive Officer for Medicare of Centene Corporation, a Fortune 100 healthcare enterprise. Prior to Centene, Mr. Moller was President of Fidelis SecureCare, a growth equity-backed Medicare Institutional Special Needs plan providing insurance plans for enrollees with multiple chronic diseases. Before Fidelis, Mr. Moller was Chief Operations Officer of the Express Scripts Insurance Company, where he launched and grew the company’s Medicare program, including its national Prescription Drug Plan, now a multi-billion-dollar business and the largest in the U.S. Earlier in his career, Mr. Moller held the position of Chief Marketing Officer at consumer-directed pioneer, HealthMarkets, Inc., and at regional operating units of Oxford Health Plans. Mr. Moller is a board member of 340(B) Technologies as well as various non-profits. He has a B.A. in Economics and English from Boston College and a M.B.A. from Harvard Business School. “We welcome Glen to DarioHealth, and we are honored that he has accepted the board position. Glen brings invaluable expertise to DarioHealth in the field of healthcare, both with respect to data-driven technologies and in insurance and managed care. As a visionary in the industry, he has built and led multi-billion dollar businesses through multiple stages of growth. We believe his know-how, insights and network will serve to support the roll out of our digital health platform to healthcare providers and payers,” stated DarioHealth CEO, Erez Raphael. “I believe that DarioHealth is well timed with the right technology and offering in the market for digital health solutions today. From diabetes care to serving other chronic conditions, the company’s data-based, patient-friendly platform is an integrated solution that we believe can significantly lower costs for providers. I am pleased to have the opportunity to offer my guidance to DarioHealth,” commented Mr. Moller. About DarioHealth Corp. DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/. Cautionary Note Regarding Forward-Looking Statements This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, when the Company states that it believes that Mr. Moller’s know-how, insights and network will serve to support the roll out of its digital health platform to healthcare providers and payers and its belief that its data-based, patient-friendly platform is an integrated solution that can significantly lower costs for providers, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. DarioHealth Corporate Contact:
SOURCE DarioHealth Corp. | ||
Company Codes: Berlin:LS1N, NASDAQ-SMALL:DRIO, Stuttgart:LS1N, OTC-BB:DRIO, OTC-QB:DRIO |
View original content:
